{"id":19879,"date":"2025-06-13T10:06:58","date_gmt":"2025-06-13T10:06:58","guid":{"rendered":"https:\/\/www.pidsphil.org\/home\/?page_id=19879"},"modified":"2025-11-19T23:55:43","modified_gmt":"2025-11-19T23:55:43","slug":"journal-2025-vol-26-no-1-original-articles-3","status":"publish","type":"page","link":"https:\/\/www.pidsphil.org\/home\/journal-2025-vol-26-no-1-original-articles-3\/","title":{"rendered":"Journal 2025 Vol.26 No.1 Original Articles 3"},"content":{"rendered":"<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:1206.4px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-bg-blend:overlay;--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:1.92%;--awb-margin-bottom-large:0px;--awb-spacing-left-large:1.92%;--awb-width-medium:100%;--awb-spacing-right-medium:1.92%;--awb-spacing-left-medium:1.92%;--awb-width-small:100%;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-text fusion-text-1\"><p><b><strong><span style=\"color: #800000;\">Journal 2025 Vol.26 No.1<\/span><\/strong><\/b><br \/>\n<b>Outcomes of the use of Ceftazidime-avibactam among patients admitted in the neonatal intensive care unit with multidrug-resistant Klebsiella hospital-acquired sepsis <\/b><br \/>\n<em><strong>Vince Elic S. Maullon, M.D., Sally Jane Velasco-Aro, M.D.<\/strong><\/em><\/p>\n<p><b>Abstract <\/b><br \/>\n<b>Background <\/b>The use of ceftazidime-avibactam (CAZ-AVI) has been recently introduced to combat multidrug\u0002resistant organisms (MDROs) in the pediatric population. Case reports have documented the successful off-label use of CAZ-AVI in the treatment of MDRO sepsis in neonates; however, data remains to be limited, especially in the Philippines.<br \/>\n<b>Objectives:<\/b> This study aims to explore the effects of CAZ-AVI on clinical outcomes including mortality rate, length of hospital stay since treatment initiation, and bacteriological eradication among patients admitted at the NICU with MDR Klebsiella hospital-acquired sepsis. Other objectives include comparing these outcomes betwee those who received CAZ-AVI (in combination with aztreonam, ATM) and those who received other 2nd line MDR\u0002antibiotic regimens used for carbapenem-resistant Klebsiella growths, as well as exploring the association of factors such as gestational age and age at sepsis diagnosis of patients with their outcomes post-treatment with CAZ-AVI\u00b1 ATM.<br \/>\n<b>Methodology: <\/b>This is a retrospective cohort study of admitted patients in a neonatal intensive care unit of a tertiary hospital with MDR Klebsiella hospital-acquired sepsis across a two-year period. A review of medical records was done, and data were collected and analyzed.<br \/>\n<b>Results: <\/b>There were a total 11 patients treated with CAZ-AVI \u00b1 ATM compared with 11 patients given other 2nd line antibiotic treatment regimens. The use of CAZ-AVI \u00b1 ATM exhibited a trend towards a decreased mortality rate (54.5%, p = 0.17), shorter length of hospital stays from treatment initiation (30.7 days, p = 0.50), and increased bacteriological eradication rates (63.6%, p &lt; 0.05), compared with other 2nd line antibiotic treatment regimens, regardless of gestational age and age at sepsis diagnosis.<br \/>\n<b>Conclusion: <\/b>The use of CAZ-AVI \u00b1 ATM showed a more favorable trend compared with other 2nd line antimicrobials for with MDR Klebsiella hospital-acquired sepsis. These observations, however, require further confirmation with a prospective study, a longer study period, and an increase in sample size.<\/p>\n<p><b>KEYWORDS: <\/b><i>Ceftazidime-avibactam, multidrug-resistant Klebsiella hospital-acquired sepsis, neonates<\/i><br \/>\n<a href=\"https:\/\/doi.org\/10.56964\/pidspj20262601004\"><strong>https:\/\/doi.org\/10.56964\/pidspj20252601004<\/strong><\/a><br \/>\n<strong><a href=\"https:\/\/www.pidsphil.org\/home\/wp-content\/uploads\/2025\/11\/5-Kleb-Sepsis.pdf\" target=\"_\" rel=\"noopener\">View Full Article in PDF format<\/a>\u00a0<\/strong><\/p>\n<\/div><\/div><\/div><\/div><\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-19879","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/www.pidsphil.org\/home\/wp-json\/wp\/v2\/pages\/19879","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pidsphil.org\/home\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.pidsphil.org\/home\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.pidsphil.org\/home\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pidsphil.org\/home\/wp-json\/wp\/v2\/comments?post=19879"}],"version-history":[{"count":7,"href":"https:\/\/www.pidsphil.org\/home\/wp-json\/wp\/v2\/pages\/19879\/revisions"}],"predecessor-version":[{"id":20296,"href":"https:\/\/www.pidsphil.org\/home\/wp-json\/wp\/v2\/pages\/19879\/revisions\/20296"}],"wp:attachment":[{"href":"https:\/\/www.pidsphil.org\/home\/wp-json\/wp\/v2\/media?parent=19879"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}